Phase 2b/3 Trial Testing IRLAB’s IRL790 in Levodopa-induced Dyskinesia to Start in 2020

Following the positive results of a Phase 2a clinical trial, IRLAB Therapeutics is planning a Phase 2b/3 study for the first half of 2020 that will test IRL790 as an oral treatment candidate for Parkinson’s patients with levodopa-induced dyskinesia (LID) — involuntary, jerky movements that can…

IRL790 Is Safe, Reduces Levodopa-induced Dyskinesia in Parkinson’s, Phase 1b Trial Shows

IRL790, Integrative Research Laboratories‘ investigational treatment for Parkinson’s disease patients, was safe and reduced levodopa-induced dyskinesia, a Phase 1b trial shows. The results were published in the journal npj Parkinson’s Disease in the study, “Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced…